<DOC>
	<DOCNO>NCT01926964</DOCNO>
	<brief_summary>Oncotype DX® likely become widely use Europe well Switzerland . The test currently reimburse Swiss health insurance . The propose study investigate extent adjuvant treatment recommendation breast cancer patient ER-positive tumor , make Swiss tumor board , base conventional factor , whether recommendation would change , RS result Oncotype DX® test available . In addition study approach dilemma add adjuvant CT adjuvant endocrine therapy systematic fashion . In study , St. Gallen consensus 2009 ( minor update 2011 consensus , use predefine patient suitable endocrine therapy chemo-endocrine therapy . Once result study available may help good integrate Oncotype DX® factor . Currently , unclear different factor integrate one recommendation . This study provide data usefulness test two patient group suitable hormone therapy consider hormone plus chemotherapy .</brief_summary>
	<brief_title>Adjuvant Treatment Recommendation Oncotype DX® Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients screen criterion 1 . ≥ 18 year old female patient . 2 . Resected primary breast cancer ( R0 resection ) . 3 . ERpositive breast cancer ( define least 10 % ERpositive malignant cell ) . 4 . HER2 negativity IHC ( 0 1+ ) FISH ( negative ratio ≤ 2.0 ) . 5. pN0 pN1a ( 13 positive node ) sentinel procedure axillary dissection . All patient match screen criterion record consecutively patient screen enrollment list . Patients inclusion criterion baseline data collection 1 . Signed informed consent form participation baseline data collection . In addition , follow information must available pathology report : 2 . Estimation pathologic maximum tumor diameter ( mm ) . 3 . Results ER positive tumor cell ( % ) PgR positive tumor cell ( % ) invasive component . 4 . Proliferation rate Ki67 staining ( MIB1 antibody ) % . 5 . Result modify BloomRichardsonElston ( BRE ) Grading ( Grade 1 , 2 3 ) . Patients eligibility criterion participation study Inclusion criterion 1 . Signed informed consent form participation study SAKK 26/10 . 2 . The patient consider suitable receive adjuvant chemotherapy ( ie medical contraindication chemotherapy ) . 3 . Invasive breast cancer tissue available prepare 39 section ( 35 unstained + 4 H &amp; E stain slide , thickness 5 µm ) . 4 . Performance Status : 0 1 . Exclusion criterion 1 . Pregnancy 2 . Bilateral invasive breast cancer 3. cT4 pT4 tumor . 4 . Patient current psychiatric medical diagnosis would interfere ability participate study . 5 . Known metastatic breast cancer ( M1 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Adjuvant treatment recommendation</keyword>
	<keyword>Early breast cancer</keyword>
	<keyword>Oncotype DX</keyword>
	<keyword>Genetic profiling</keyword>
</DOC>